Hrain Biotechnology, a Chinese company that specializes in the research and development of tumour immunotherapy technologies, has secured 200 million yuan ($27.97 million) in a Series B round of financing led by Chinese state-backed venture capital firm Shenzhen Venture Capital, it announced on Monday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com